The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Zebrafish models in neuropsychopharmacology and CNS drug discovery
Open accessAbstract
Despite the high prevalence of neuropsychiatric disorders, their aetiology and molecular mechanisms remain poorly understood. The zebrafish (Danio rerio) is increasingly utilized as a powerful animal model in neuropharmacology research and in vivo drug screening. Collectively, this makes zebrafish a useful tool for drug discovery and the identification of disordered molecular pathways. Here, we discuss zebrafish models of selected human neuropsychiatric disorders and drug‐induced phenotypes. As well as covering a broad range of brain disorders (from anxiety and psychoses to neurodegeneration), we also summarize recent developments in zebrafish genetics and small molecule screening, which markedly enhance the disease modelling and the discovery of novel drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“Nevertheless, SOD1 is the most well-understood gene to be associated with ALS (Rosen et al., 1993), and mutations in the SOD1 gene account for 20% of familial ALS cases (Valdmanis and Rouleau, 2008).”
BackgroundEffectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
The zebrafish reference genome sequence and its relationship to the human genome.
Howe, K., Clark, M. D., Torroja, C. F., Torrance, J., Berthelot, C., Muffato, M., Collins, J. E., Humphray, S., McLaren, K., Matthews, L., et al. (2013) · Nature · doi:10.1038/nature12111 · Cited by 5,100 · cited 1×
“The zebrafish genome, fully sequenced, shows orthologues corresponding to ~82% of disease-related genes in humans (Howe et al., 2013).”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Efficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Drugs of abuse: anatomy, pharmacology and function of reward pathways
Koob, G. F. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90060-j · Cited by 2,070
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Amygdala, medial prefrontal cortex, and hippocampal function in PTSD
SHIN, L. M., RAUCH, S. L., & PITMAN, R. K. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1364.007 · Cited by 1,203
The ascent of mouse: advances in modelling human depression and anxiety
Cryan, J. F., & Holmes, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1825 · Cited by 1,198
Rauch, S. L., Whalen, P. J., Shin, L. M., McInerney, S. C., Macklin, M. L., Lasko, N. B., Orr, S. P., & Pitman, R. K. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00828-3 · Cited by 1,111
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“However, they produce severe side effects, including tremors, paranoia and anxiety (Miyamoto et al., 2005).”
BackgroundOptogenetic investigation of neural circuits underlying brain disease in animal models
Tye, K. M., & Deisseroth, K. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3171 · Cited by 745 · cited 1×
“However, optogenetic neuromodulation in zebrafish helps future research to create robust models of complex human neuropsychiatric disorders (Tye and Deisseroth, 2012; Stewart et al., 2015c).”
BackgroundCorticosteroids in relation to fear, anxiety and psychopathology
Korte, S. M. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00002-1 · Cited by 607
Bell, E. L., Klimova, T. A., Eisenbart, J., Moraes, C. T., Murphy, M. P., Budinger, G. R. S., & Chandel, N. S. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200609074 · Cited by 568
Animal Models of Depression: Molecular Perspectives
Krishnan, V., & Nestler, E. J. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2010_108 · Cited by 528
Learned helplessness in the rat.
Seligman, M. E., & Beagley, G. (1975) · Journal of Comparative and Physiological Psychology · doi:10.1037/h0076430 · Cited by 481
The promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434 · cited 2×
“NAC administration to adult zebrafish prevents stress-induced anxiety (Mocelin et al., 2015), which is in line with previous reports of its clinical efficacy in depressed patients (Berk et al., 2013).”
BackgroundResultCiura, S., Lattante, S., Le Ber, I., Latouche, M., Tostivint, H., Brice, A., & Kabashi, E. (2013) · Annals of Neurology · doi:10.1002/ana.23946 · Cited by 333 · cited 2×
“For instance, the loss of function of the zebrafish orthologue C9orf72 leads to axonal degeneration of motor neurons and is accompanied by decreased swim speed and motility of larval zebrafish (Ciura et al., 2013).”
BackgroundTreatment outcomes for primary care patients with major depression and lifetime anxiety disorders.
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.10.1293 · Cited by 312 · cited 1×
“Furthermore, althoughmany treatments for anxiety disorders exist, approximately 30% of patients show no improvement (Brown et al., 1996).”
BackgroundAhmed, T., & Gilani, A.-H. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.09.010 · Cited by 301
Cortisol and depression: three questions for psychiatry
Herbert, J. (2013) · Psychological Medicine · doi:10.1017/s0033291712000955 · Cited by 301 · cited 2×
“There is mounting evidence implicating alterations in the neuroendocrine system in various brain disorders, including depression (Herbert, 2013; Holsboer, 2001), anxiety (Hek et al.”
BackgroundTreatment-resistant anxiety disorders
Bystritsky, A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001852 · Cited by 289 · cited 4×
“The first line of treatment for anxiety disorders is typically a regimen of SSRIs or cognitive behavioural therapy (Bystritsky, 2006).”
BackgroundInfluentialPortavella, M., Torres, B., & Salas, C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4930-03.2004 · Cited by 283
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.10.1485 · Cited by 263
Kubo, F., Hablitzel, B., Dal Maschio, M., Driever, W., Baier, H., & Arrenberg, A. B. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.043 · Cited by 182 · cited 1×
“To date, optogenetic studies in zebrafish have largely focused on several simpler behaviours, such as escape (Douglass et al., 2008), locomotion (Arrenberg et al., 2009; Ljunggren et al., 2014) and sensory processing (Kubo et al., 2014).”
BackgroundImpact of early adversity on glucocorticoid regulation and later mental disorders
Strüber, N., Strüber, D., & Roth, G. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.015 · Cited by 173
Forebrain evolution in bony fishes
Northcutt, R. G. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.10.058 · Cited by 173
Ter Horst, G. J., & Luiten, P. G. M. (1987) · Brain Research Bulletin · doi:10.1016/0361-9230(87)90190-0 · Cited by 164
Anxiety disorders and salivary cortisol levels in older adults: a population-based study
Hek, K., Direk, N., Newson, R. S., Hofman, A., Hoogendijk, W. J. G., Mulder, C. L., & Tiemeier, H. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.06.006 · Cited by 116
Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease
Voisin, T., & Vellas, B. (2009) · Drugs & Aging · doi:10.2165/0002512-200926020-00005 · Cited by 89
Cited by
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567
Zebrafish Larvae as a Behavioral Model in Neuropharmacology
Basnet, R. M., Zizioli, D., Taweedet, S., Finazzi, D., & Memo, M. (2019) · Biomedicines · doi:10.3390/biomedicines7010023 · Cited by 376
Fontana, B. D., Mezzomo, N. J., Kalueff, A. V., & Rosemberg, D. B. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.004 · Cited by 272
Self-citation
Metadata
- Authors
- Khan, K. M., Collier, A. D., Meshalkina, D. A., Kysil, E. V., Khatsko, S. L., Kolesnikova, T., Morzherin, Y. Y., Warnick, J. E., Kalueff, A. V., & Echevarria, D. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-04-05
- Volume
- 174
- Issue
- 13
- Pages
- 1925-1944
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2589167692
- Cited by
- 204
- References
- 33
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.